This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Juvenile Ankylosing Spondylitis연소성 강직척추염 (연소성강직척추염)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: M08.1 | Special Copayment Reduction: V133 (rare disease)
B. Synonyms—
C. Adult onsetLikelihood of first onset in adulthood low — by definition, juvenile ankylosing spondylitis has onset before age 16, but spinal involvement often becomes evident in late adolescence to early adulthood, so the diagnosis is sometimes established in adulthood. It is a disease continuous with adult ankylosing spondylitis (AS).
1. History

Juvenile Ankylosing Spondylitis (JAS), occurring before age 16, is ankylosing spondylitis (Ankylosi…

2. Causes

HLA-B27 plays a key role in the pathogenesis of juvenile ankylosing spondylitis. HLA-B27, located in the MHC I region of chromosome 6, is an HLA class…

3. Genetics

The most important genetic risk factor for juvenile ankylosing spondylitis is HLA-B27. In about 80–95% of patients with JAS, HL…

4. General epidemiology

Juvenile ankylosing spondylitis (JAS/ERA) accounts for about 10–15% of all JIA. In sex distribution, boys are 2–3 times more commonly affected than girls,…

5. Pathophysiology

In the pathophysiology of juvenile ankylosing spondylitis, enthesis inflammation plays a central role. The enthesis is where tendons, ligaments…

6. Symptoms

Unlike adult AS, the early symptoms of juvenile ankylosing spondylitis are dominated by peripheral joint involvement of the lower limbs and enthesis pain, and low back pain…

7. Signs

On physical examination, swelling and limited motion of the hip, knee and ankle joints and enthesis tenderness are the main signs. Tenderness at the Achilles tendon insertion (tenderness…

8. Screening

Screening for juvenile ankylosing spondylitis is performed in boys (aged 8–16) with persistent lower limb joint pain or swelling, especially enthesis pain. HLA-B27 test…

9. Diagnosis

The diagnosis of juvenile ankylosing spondylitis applies the ILAR ERA criteria or the juvenile ankylosing spondylitis criteria. ILAR ERA criteria: ① arthritis + enthesitis, or…

10. Treatment

Treatment of juvenile ankylosing spondylitis aims to suppress joint inflammation, preserve spine and hip function and relieve enthesis pain. NSAIDs are the first-line treatment, and indometha…

11. Prognosis

The long-term prognosis of juvenile ankylosing spondylitis may be somewhat worse than that of adult ankylosing spondylitis, and especially when hip involvement occurs early, the need for joint replacement…

12. Prevention

Prevention in juvenile ankylosing spondylitis focuses on preventing spinal ankylosis and joint damage. Regular stretching and low-impact aerobic exercise such as swimming and cycling … spinal…

13. References10 papers in major international journals.

1. History

Juvenile Ankylosing Spondylitis (JAS) is Ankylosing Spondylitis (AS) occurring before age 16 and is included in the Enthesitis-related Arthritis (ERA) category of the ILAR classification. The history of ankylosing spondylitis dates back to descriptions by Karim König of Germany in 1693 and Vladimir Bekhterev of Russia in 1899, and it is also called Bekhterev's disease (Bjekhterev's disease). Unlike adult AS, ankylosing spondylitis in children prominently involves the large joints of the lower limbs and the entheses, while spinal and sacroiliac involvement is less marked early on, so diagnosis is often delayed.

HLA-B27 was discovered in 1973 to be the strongest genetic risk factor for ankylosing spondylitis, and HLA-B27 subsequently came to play a key role in understanding the pathogenesis and in the diagnosis of ankylosing spondylitis. Along with the introduction of biologics, IL-17A blockers (secukinumab, ixekizumab), IL-12/23 blockers (ustekinumab) and JAK inhibitors (tofacitinib, upadacitinib) have been approved for adult ankylosing spondylitis, and clinical trials are underway in pediatric ERA/JAS as well.

In East Asia, including Korea, the frequency of HLA-B27 positivity is lower than in white populations, but the risk of developing ankylosing spondylitis in HLA-B27-positive individuals is similar. Spondyloarthritis experts currently understand JAS as continuous with pediatric peripheral SpA and adult AS within the 'spondyloarthritis (SpA)' spectrum.

2. Causes

HLA-B27 plays a key role in the pathogenesis of juvenile ankylosing spondylitis. HLA-B27 is an HLA class I gene located in the MHC I region of chromosome 6, with about 100 subtypes. In HLA-B27-positive individuals, the risk of developing ankylosing spondylitis is about 50–100 times higher than in the general population, but only 5–10% of HLA-B27-positive individuals actually develop ankylosing spondylitis. Proposed pathogenic mechanisms of HLA-B27 include ① activation of specific CD8+ T-cell autoreactivity by extracellular expression of HLA-B27, ② activation of the UPR (unfolded protein response) and IL-23 production due to misfolding of HLA-B27 in the endoplasmic reticulum (ER misfolding) and ③ NK-cell activation by expression of HLA-B27 homodimers.

As an environmental factor, there is a hypothesis that gut bacteria (especially Klebsiella pneumoniae) trigger immune activation through molecular mimicry with HLA-B27. The IL-23/IL-17 axis is the core pathway of enthesis inflammation: IL-17A secretion begins from γδ T cells and innate lymphoid cells (ILC3) resident in enthesis tissue, leading to CXCL1-mediated neutrophil recruitment and secretion of TNF-α and IL-6. This process results in bone erosion and reactive bone formation (new bone formation, syndesmophytes), causing spinal ankylosis.

3. Genetics

The most important genetic risk factor for juvenile ankylosing spondylitis is HLA-B27. HLA-B27 is positive in about 80–95% of patients with JAS, and the HLA-B27*02 and B27*05 subtypes are strongly pathogenic. HLA-B27-negative ankylosing spondylitis also exists, in which other HLA risk alleles (B39, B38, A2) or non-HLA genes may be involved. As non-HLA risk genes, polymorphisms of ERAP1 (endoplasmic reticulum aminopeptidase 1), IL23R, CARD9 and TNFRSF1A have been identified in GWAS. There is familial clustering, and because the risk of ankylosing spondylitis is increased in children of HLA-B27-positive parents, genetic counseling is meaningful. In HLA-B27-positive children with low back pain or enthesis pain, early referral to a rheumatologist is recommended.

4. General epidemiology

Juvenile ankylosing spondylitis (JAS/ERA) accounts for about 10–15% of all JIA. In sex distribution, boys are 2–3 times more commonly affected than girls, and the age of onset is usually 8–16 years, mainly in boys in late school age. HLA-B27 positivity varies by region, differing among white populations (about 8%), some Asian populations (about 4–8%) and healthy Koreans (about 6–8%). The population-based prevalence of ankylosing spondylitis overall (adult + pediatric) in Korea is reported to be about 0.1–0.2%. In more than half of patients with JAS, the disease persists into adulthood, and the rate of transition to adult AS is high. In Korea, registration and treatment under Special Copayment Reduction V133 are possible.

5. Pathophysiology

In the pathophysiology of juvenile ankylosing spondylitis, enthesis inflammation plays a central role. The enthesis is where tendons, ligaments and joint capsules attach to bone and is the preferred site of early inflammation in ankylosing spondylitis. IL-23-responsive innate lymphoid cells (ILC3) and γδ T cells reside in the enthesis and, upon IL-23 signaling, secrete IL-17A and TNF-α, which trigger a cascade of neutrophil recruitment, bone erosion and reactive bone formation (syndesmophytes). There is a hypothesis that impaired immunoregulatory function of gut bacteria (dysbiosis) contributes to the development of ankylosing spondylitis through a gut-enthesis immune pathway. In the spine, during repeated cycles of inflammation and repair at the ligament-bone junction, TGF-β and BMP signaling induce excessive bone formation (syndesmophytes, bone bridging), leading to spinal ankylosis.

6. Symptoms

Unlike adult AS, the early symptoms of juvenile ankylosing spondylitis are dominated by peripheral joint involvement of the lower limbs and enthesis pain, and low back pain and spinal symptoms appear later. The main lower limb joints involved are the hip, knee, ankle and toe joints, and ankle and heel enthesis pain is characteristic. Pain at the Achilles tendon insertion (calcaneal enthesitis) and at the plantar fascia insertion is particularly common. Hip involvement is a serious prognostic factor, and early treatment is important for preventing joint destruction. Limitation of the lumbar and thoracic spine and low back pain often appear after several years.

Acute anterior uveitis occurs in about 25–35%, and the symptomatic form presenting with pain, redness and photosensitivity (common in adult AS) also occurs in children. This differs from the asymptomatic chronic uveitis of RF-negative oligoarticular JIA. Mild systemic symptoms (fever, weight loss, fatigue) may accompany it. Coexisting inflammatory bowel disease (Crohn disease, ulcerative colitis) is observed in about 5–10%.

7. Signs

On physical examination, swelling and limited motion of the hip, knee and ankle joints and enthesis tenderness are the main signs. Tenderness at the Achilles tendon insertion (tenderness at calcaneal insertion), plantar fascia tenderness, pes anserinus tenderness and iliac crest enthesis tenderness are characteristically observed. On spinal examination, reduced lumbar lordosis, an abnormal Schober test and limited chest expansion (≤2.5 cm) suggest spinal involvement. Positive provocation tests for sacroiliac joint tenderness are observed in JAS. Laboratory findings characteristically include HLA-B27 positivity (about 80–95%) and elevated ESR and CRP, while RF and ANA are negative. On radiography and MRI, sacroiliac bone erosion, fat deposition and ankylosis are used for diagnosis and disease monitoring.

8. Screening

Screening for juvenile ankylosing spondylitis is performed in boys (aged 8–16) with persistent lower limb joint pain or swelling, especially enthesis pain. HLA-B27 testing is central to diagnostic screening. It includes inflammatory markers (ESR, CRP), blood counts, RF (to confirm negativity) and ANA (to confirm negativity). Sacroiliac joint MRI can detect inflammation and fat deposition earlier than radiography and is preferred as screening imaging. Sacroiliac radiographs may be negative early, and radiographically positive findings often appear only after several years. With symptoms of anterior uveitis (eye redness, pain, photosensitivity), immediate ophthalmology referral is needed.

9. Diagnosis

The diagnosis of juvenile ankylosing spondylitis applies the ILAR ERA criteria or the juvenile ankylosing spondylitis criteria. ILAR ERA criteria: ① arthritis + enthesitis, or ② either arthritis or enthesitis + at least 2 of the following: HLA-B27 positivity, onset in a boy aged 8 or older, family history (first- or second-degree relatives) of ankylosing spondylitis/ERA/sacroiliitis/inflammatory bowel disease/Reiter syndrome, acute (symptomatic) anterior uveitis, boy aged 8 or older. Inflammatory findings on sacroiliac joint MRI (bone marrow edema, fat deposition) are decisive for early diagnosis. The differential diagnosis includes reactive arthritis, septic arthritis, RF-positive JIA and traumatic arthritis.

10. Treatment

Treatment of juvenile ankylosing spondylitis aims to suppress joint inflammation, preserve spine and hip function and relieve enthesis pain. NSAIDs are the first-line treatment, mainly indomethacin and naproxen. When there is an insufficient response to NSAIDs or hip involvement, treatment is switched to biologics. TNF blockers (etanercept, adalimumab, infliximab) have received FDA approval for ERA/JAS and are used as first-line biologic therapy. The IL-17A blocker (secukinumab) has received first approval for adult AS and is in clinical trials for pediatric ERA. Intra-articular steroid injections, physical therapy (posture education, chest expansion exercises) and rehabilitation are essential treatment components. Methotrexate is effective for peripheral arthritis but has limited efficacy for spinal inflammation.

11. Prognosis

The long-term prognosis of juvenile ankylosing spondylitis may be somewhat worse than that of adult ankylosing spondylitis, and especially when hip involvement occurs early, the need for joint replacement increases. Since the introduction of TNF blockers, suppression of radiographic progression and preservation of function have greatly improved. In about 50%, active disease persists into adulthood, often meeting adult AS criteria. When it progresses to sacroiliac ankylosis and spinal ankylosis (bamboo spine), functional impairment becomes severe. Uveitis carries a risk of recurrence into adulthood, requiring regular ophthalmologic follow-up. Maintaining spinal mobility through regular physical therapy and exercise is key to long-term preservation of function.

12. Prevention

Prevention in juvenile ankylosing spondylitis focuses on preventing spinal ankylosis and joint damage. Regular stretching and low-impact aerobic exercise such as swimming and cycling are essential for maintaining spinal mobility. Suppressing radiographic progression through early introduction of TNF blockers is key to long-term preservation of function. In children with a family history of HLA-B27 positivity, early referral to a rheumatologist is recommended when exercise-related enthesis pain persists. Infection prevention during immunosuppressive treatment (including tuberculosis screening) is essential. Because smoking has been reported as an aggravating factor for ankylosing spondylitis, smoking cessation education from adolescence is recommended.

13. References

  1. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390-392. PMID: 14760812.
  2. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767-778. DOI: 10.1016/S0140-6736(07)60363-8. PMID: 17336654.
  3. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis. Arthritis Care Res. 2011;63(4):465-482. DOI: 10.1002/acr.20459. PMID: 21452260.
  4. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202-1209. PMID: 9214419.
  5. Wallace CA, Ruperto N, Giannini EH. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31(11):2290-2294. PMID: 15517650.
  6. Gowdie PJ, Tse SM. Juvenile idiopathic arthritis. Pediatr Clin North Am. 2012;59(2):301-327. DOI: 10.1016/j.pcl.2012.03.014. PMID: 22560573.
  7. Klein A, Minden K, Hospach A, et al. Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis. Ann Rheum Dis. 2020;79(7):969-974. DOI: 10.1136/annrheumdis-2019-216579. PMID: 32350026.
  8. Consolaro A, Ruperto N, Bazso A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(5):658-666. DOI: 10.1002/art.24516. PMID: 19405003.
  9. Nigrovic PA, Mannion M, Prince FHM, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis. Arthritis Rheum. 2011;63(2):545-555. DOI: 10.1002/art.30128. PMID: 21280009.
  10. Horneff G, De Buck M, Foeldvari I, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis. Ann Rheum Dis. 2009;68(4):519-525. DOI: 10.1136/ard.2007.087593. PMID: 18445619.